Bengaluru based Sami-Sabinsa, a pioneer in the nutraceutical and cosmeceutical industries, has expanded its large portfolio of intellectual property with a new patent granted in Mexico for the company’s Boswellia serrata ingredient Boswellin® PS.
This patent, MX328842, is for a synergistic composition containing boswellic acids and polysaccharides obtained from the Boswellia species for its property to downregulate pro-inflammatory markers. This includes, for example, PGE2, which drives the inflammatory process in different diseases.
“Inflammation is an underlying cause of many health conditions throughout the world,” said Dr. Muhammed Majeed, Founder and Chairman of Sami-Sabinsa Group. “By applying modern research to ancient Ayurvedic knowledge Sami-Sabinsa has been able to provide natural solutions, including the Boswellin PS ingredient, to this common condition.”
This property of the composition was also awarded with a patent grant in Australia, Canada, Eurasia and Taiwan.